Trial Profile

A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bedaquiline (Primary) ; Linezolid (Primary) ; Pretomanid (Primary) ; Clofazimine; Moxifloxacin
Indications Pulmonary tuberculosis
Focus Adverse reactions; Therapeutic Use
Acronyms TB-PRACTECAL

30 Apr 2024 Status changed from discontinued to recruiting.
22 Dec 2022 Primary endpoint has been met. (Stage 2: Percentage of patients with an unfavourable outcome (failure, death, recurrence, loss to follow-up), as per Results published in the New England Journal of Medicine
22 Dec 2022 Results published in the New England Journal of Medicine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com